Abstract 246P
Background
First-line (1L) platinum-based chemotherapy (CT) improves survival in metastatic urothelial cancer (mUC). Cisplatin eligibility for pivotal clinical trials excludes renal impairment (eGFR≤60mL/min). Impact of renal impairment on prescribing in the real world is unknown.
Methods
A cohort of mUC patients (pts) having 1L CT was extracted from BLADDA, Australia’s multisite, urothelial cancer registry. Clinicodemographic and outcome data were analysed using descriptive statistics. Statistical significance was defined by p≤0.05. Progression-free (PFS) and overall (OS) survival was defined as time to progression or death from 1L CT.
Results
Our cohort included 132 pts, median age 70 (range 29-86), predominantly male (76%), ECOG 0-1 (88%) and de novo metastatic (58%). Renal function was known in 104 pts; 47% had eGFR≤60 (eGFR 40-60: 34%; eGFR≤40: 13%). Most pts received 1L platinum-based CT (76%). In pts without renal impairment (eGFR>60), carboplatin/gemcitabine was more common than cisplatin/gemcitabine (GC) (40% vs 31%, p=0.3). In pts with renal impairment (eGFR ≤60), carboplatin/gemcitabine remained the most common (33%), followed by GC (18%) and split dose GC (18%). Renal function did not predict cisplatin use (>60: 38% vs ≤60: 37%; OR 1.1, p=0.9), nor impact trial enrolment (>60: 6% vs ≤60: 12%; OR 0.4, p=0.2). Dose reductions were numerically more common in renal impairment (>60: 35% vs ≤60: 49%; OR 2, p=0.2). Renal impairment did not impact response rate (>60: 65% vs ≤60: 68%; p=0.8) but resulted in shorter PFS (14 months, 95% CI 9-19 vs 7, 95% CI 6-8) and OS (37 months, 95% CI 29-NE vs 27, 95% CI 22-33). Table: 246P
All patients (n=132) | eGFR known at 1L treatment (n= 104) | |||
>60 (n= 55) (%) | <60 (n =49) | |||
40-60 (n=35) (%) | <40 (n=14) (%) | |||
1L treatment – Cisplatin-based GC GC (split dose) MVAC/ddMVAC Carboplatin/gemcitabineTrialPembrolizumabOther | 47 (36) 33 (25) 10 (8) 4 (3) 50 (38)11 (8)14 (11)10 (8) | 21 (38) 16 (29) 1 (2) 4 (7) 22 (40)3 (6)7 (13)2 (4) | 11 (31) 6 (17) 5 (14) 0 13 (37)6 (17)3 (9)2 (6) | 7 (50) 3 (21) 4 (29) 0 3 (21)001 (7) |
Median PFS– months (95%CI) | 9 (6-11) | 14 (9-19) | 7 (6-8) | 7 (4-9) |
Median OS – months (95%CI) | 28.8 (21-37) | 37 (29-NE) | 29 (13-45) | 24 (23-25) |
Conclusions
In this real-world analysis, pts receiving 1L CT with impaired renal function had inferior PFS and shortened OS, which was not explained by differences in cisplatin use. Our study is limited by few pts with eGFR<40 and did not evaluate those unfit for CT. Further research to determine optimal 1L therapy in this cohort is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, BMS, Pfizer, Merck.
Disclosure
A.J. Weickhardt: Financial Interests, Personal, Advisory Board: Merck, Ipsen, Pfizer; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Coordinating PI, PCR MIB funding: Merck. P. Gibbs: Financial Interests, Personal, Advisory Board: Merck, Bayer, Amgen, Servier, Haystack Oncology; Financial Interests, Personal, Invited Speaker: MSD. B. Tran: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Astellas, Bayer, BMS, Ipsen, IQVIA, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Tolmar, Sanofi Ammunix; Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BMS, Merck, Pfizer; Financial Interests, Institutional, Research Grant: Amgen, Astellas, AstraZeneca, Bayer, BMS, Genentech, Ipsen, Janssen, Pfizer, MSD; Financial Interests, Personal, Steering Committee Member: CG Oncology, Janssen, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract